Gilead touts piv­otal da­ta for new kind of HIV ther­a­py, open­ing to­wards large po­ten­tial mar­ket

Pan­dem­ic aside, the last cou­ple years at Gilead have been all about ex­pan­sions: Mov­ing be­yond the HIV and he­pati­tis C an­tivi­rals that made them in­to a $77 bil­lion com­pa­ny and in­to the im­munol­o­gy and on­col­o­gy treat­ments that have be­come biotech’s bread and but­ter.

Still, key HIV projects have con­tin­ued as the Cal­i­for­nia biotech looks to stay on top of a field that still earns them north of $15 bil­lion per year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.